Poumon à petites cellules

  • Accueil
  • Poumon à petites cellules
  • TIGOS

TITRE (EN) A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer.
PROTOCOLE ID TIGOS
CLINICAL TRIAL.gov ID NCT06646276
TYPE(S) DE CANCER Poumon à petites cellules
PHASE Phase III
TYPE D'ÉTUDE Clinique
INSTITUTION CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
305, rue Saint-Vallier, CP 5006
VILLE Chicoutimi
INVESTIGATEUR(RICE) PRINCIPAL(E) Marc Trudeau
COORDONATEUR(RICE) Sabrina Côté
sabrina.cote.inf@ssss.gouv.qc.ca
418-541-1000 poste 3065
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
  • Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
  • Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system
CRITÈRES D'EXCLUSION (EN)
  • Participants have already received certain types of treatment for extensive stage small cell lung cancer
  • Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy
  • Other protocol-defined Inclusion/Exclusion criteria apply.